Ized, multicenter, double-blind phase study of palbociclib (PD-0332991), plus letrozole vs
Ized, multicenter, double-blind phase study of palbociclib (PD-0332991), plus letrozole vs placebo plus letrozole for postmenopausal females with ER optimistic, HER2 damaging MBC who have not received any prior systemic…